WHO Pharmaceuticals Newsletter
(No. 5 & 6, 2008)
This is a consolidated volume that combines issues 5 & 6 of the newsletter. It covers new safety information and regulatory decisions in countries taken these last two months: UK medicines authority conclude that the paracetamol-asthma study needs further validation; rimonabant is suspended due to serious psychiatric events associated with its use; and Australia records new reports of tendon disorders with fluoroquinolones.
In the Feature article, the Signal Reviewer cautions that thrombotic events reported with drotrecogin may in fact represent a manifestation of the underlying disease process, rather than an adverse reaction.
With this last issue for the year, we wish you a healthy holiday season and thank you for your interest in our work.